Department of Medicine, Intermountain Medical Center, 5169 South Cottonwood Street, Suite 300, Murray, UT 84107, USA.
Clin Chest Med. 2010 Dec;31(4):675-89. doi: 10.1016/j.ccm.2010.07.005.
Venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, is a leading cause of preventable morbidity and mortality following hospitalization. In the last decade, investigators have used randomized controlled trials to assess the efficacy and safety of various methods of VTE prevention for more than 20,000 medical patients. Identifying medical patients at risk for VTE and providing effective prophylaxis is now an important health care priority to reduce the burden of this morbid and sometimes fatal disease. Pharmacologic prophylaxis is the mainstay of VTE prevention. It is effective, safe, and cost effective. Multiple scientific guidelines support VTE prophylaxis in medical patients. Regulatory and accreditation agencies have mandated that hospitals use formalized systems to assess VTE risk and provide clinically appropriate prophylaxis measures to patients at risk.
静脉血栓栓塞症（VTE）包括深静脉血栓形成和肺栓塞，是住院后可预防的发病率和死亡率的主要原因。在过去的十年中，研究人员使用随机对照试验评估了 20000 多名内科患者中多种 VTE 预防方法的疗效和安全性。识别有 VTE 风险的内科患者并提供有效的预防措施，现已成为减少这种严重且有时致命疾病负担的重要医疗保健重点。药物预防是 VTE 预防的主要方法。它是有效、安全且具有成本效益的。多项科学指南支持对内科患者进行 VTE 预防。监管和认证机构已要求医院使用规范化系统来评估 VTE 风险，并为有风险的患者提供临床适宜的预防措施。
